Adjuvant Therapy for Renal Cell Carcinoma

Seminars in Oncology

Volumn 33, Issue 5, 2006, Pages 576-582

  Jacobsohn, Kenneth M ^a   Wood, Christopher G ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DOXORUBICIN; HEAT SHOCK PROTEIN 96 VACCINE; INTERLEUKIN 2; MEDROXYPROGESTERONE; MONOCLONAL ANTIBODY G250; SORAFENIB; SUNITINIB; TEGAFUR; THALIDOMIDE; UNCLASSIFIED DRUG; URACIL; VACCINE; VINBLASTINE;

ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CLINICAL TRIAL; DERMATITIS; HAND FOOT SYNDROME; HORMONAL THERAPY; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; METASTASIS; MOLECULAR DYNAMICS; NEPHRECTOMY; NEUROTOXICITY; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED STATES;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; RADIOTHERAPY, ADJUVANT;

EID: 33749451335     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.06.005     Document Type: Article

References (55)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. In: Ries L.A.G., Eisner M.P., Kosary C.L., et al. (Eds). SEER Cancer Statistics Review, 1975-2001 (2004), National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2001 http://seer.cancer.gov/csr/1975_2001
3. Motzer R.J., Bander N.H., and Nanus D.M. Renal-cell carcinoma. N Engl J Med 335 (1996) 865-875
4. Linehan W.M., Walther M.M., and Zbar B. The genetic basis of cancer of the kidney. J Urol 170 (2003) 2163-2172
5. Rabinovitch R., Zelefsky M.J., Gaynor J.J., et al. Patterns of failure following surgical resection of renal cell carcinoma: Implications for adjuvant local and systemic therapy. J Clin Oncol 12 (1994) 206-212
6. Levy D.A., Slaton J.W., Swanson D.A., et al. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 159 (1998) 1163-1167
7. Zisman A., Pantuck A.J., Dorey F., et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19 (2001) 1649-1657
8. Frank I., Blute M.L., Cheville J.C., et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score. J Urol 168 (2002) 2395-2400
9. Kattan M.W., Reuter V., Motzer R.J., et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 166 (2001) 63-67
10. Cindolo L., de la Taille A., Messina G., et al. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int 92 (2003) 901-905
11. Yaycioglu O., Roberts W.W., Chan T., et al. Prognostic assessment of nonmetastatic renal cell carcinoma: A clinically based model. Urology 58 (2001) 141-145
12. Finney R. The value of radiotherapy in the treatment of hypernephroma-A clinical trial. Br J Urol 45 (1973) 258-269
13. Kjaer M., Iversen P., Hvidt V., et al. A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. Scand J Urol Nephrol 21 (1997) 285-289
14. Aref I., Bociek R.G., and Salhani D. Is post-operative radiation for renal cell carcinoma justified?. Radiother Oncol 43 (1997) 155-157
15. Pizzocaro G., Piva L., and Di Fronzo G. Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J Urol 138 (1987) 1379-1381
16. Yagoda A., Abi-Rached B., and Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 22 (1995) 42-60
17. Asakura T., Imai A., Ohkubo-Uraoka N., et al. Relationship between expression of drug-resistance factors and drug sensitivity in normal human renal proximal tubular epithelial cells in comparison with renal cell carcinoma. Oncol Rep 14 (2005) 601-607
18. Masuda F., Nakada J., Kondo I., et al. Adjuvant chemotherapy with vinblastine Adriamycin and UFT for renal-cell carcinoma. Cancer Chemother Pharmacol 30 (1992) 477-479
19. Rosenberg A. Principles of management: Biological therapy. In: DeVita Jr. V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer Principles and Practice of Oncology. (ed 5). (1997), Lippincott-Raven, Philadelphia, PA 349-373
20. Sanchez-Ortiz R.F., Tannir N., Ahrar K., et al. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: An in situ tumor vaccine?. J Urol 170 (2003) 178-179
21. Vogelzang N.J., Priest E.R., and Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: A case with 5-year followup. J Urol 148 (1992) 1247-1248
22. Bleumer I., Oosterwijk E., De Mulder P., et al. Immunotherapy for renal cell carcinoma. Eur Urol 44 (2003) 65-75
23. Vuky J., and Motzer R.J. Cytokine therapy in renal cell cancer. Urol Oncol 5 (2000) 249-257
24. Basting R., Corvin S., Handel D., et al. Adjuvant immunotherapy in renal cell carcinoma-Comparison of interferon alpha treatment with an untreated control. Anticancer Res 19 (1999) 1545-1548
25. Pizzocaro G., Piva L., Colavita M., et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: A multicentric randomized study. J Clin Oncol 19 (2001) 425-431
26. Messing E.M., Manola J., Wilding G., et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: An Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21 (2003) 1214-1222
27. Jeon S.H., Chang S.G., and Kim J.I. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma. Anticancer Res 19 (1999) 5593-5597
28. Migliari R., Muscas G., Solinas A., et al. Is there a role for adjuvant immunochemotherapy after radical nephrectomy in pT2-3N0M0 renal cell carcinoma?. J Chemother 7 (1995) 240-245
29. van Spronsen D.J., Mulders P.F., and De Mulder P.H. Novel treatments for metastatic renal cell carcinoma. Crit Rev Oncol Hemat 55 (2005) 177-191
30. Fyfe G., Fisher S.A., Sznol M., et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13 (1995) 688-696
31. Fisher R.I., Rosenberg S.A., Sznol M., et al. High-dose aldesleukin in renal cell carcinoma: Long-term survival update. Cancer J Sci Am 3 suppl 1 (1997) S70-S72
32. Clark J.I., Atkins M.B., Urba W.J., et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A Cytokine Working Group randomized trial. J Clin Oncol 21 (2003) 3133-3140
33. Galligioni E., Quaia M., Merlo A., et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: Five-year results of a prospective randomized study. Cancer 77 (1996) 2560-2506
34. Repmann R., Goldschmidt A.J., and Richter A. Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: A 5-year follow-up analysis. Anticancer Res 23 (2003) 969-974
35. Jocham D., Richter A., Hoffmann L., et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomized controlled trial. Lancet 363 (2004) 594-599
36. Srivastava P.K. Immunotherapy for human cancer using heat shock protein-peptide complexes. Curr Oncol Rep 7 (2005) 104-108
37. Assiki V.J., Daliani D., Pagliaro L., et al. Phase II study of autologous tumor derived heat shock protein-peptide complex vaccine (HSPPC-96) for patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 22 (2003) 386 (abstr)
38. Cheson B.D. The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma. Biodrugs 19 (2005) 309-322
39. Bleumer I., Knuth A., Oosterwijk E., et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 90 (2004) 985-990
40. Oka H., Chatani Y., Hoshino R., et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 55 (1995) 4182-4187
41. Sistla A., Sunga A., Phung K., et al. Powder-in-bottle formulation of SU011248. Enabling rapid progression into human clinical trials. Drug Dev Ind Pharm 30 (2004) 19-25
42. Bollag G., Freeman S., Lyons J.F., et al. Raf pathway inhibitors in oncology. Curr Opin Investig Drugs 4 (2003) 1436-1441
43. Awada A., Hendlisz A., Gil T., et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 92 (2005) 1855-1861
44. Ahmad T., and Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 10 (2004) 6388-6392
45. Ratain M.J., Flaherty K.T., Stadler W.M., et al. Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT), ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 22 suppl 14S (2004) 4500
46. Escudier B., Szczylik C., Eisen T., et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma. J Clin Oncol 23 16S (2005) (suppl, abstr 4510)
47. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
48. Motzer R.J., Rini B.I., Michaelson M.D., et al. The SU11248 study group, phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). J Clin Oncol 23 16S (2005) (suppl, abstr 4508)
49. Amato R.J. Thalidomide therapy for renal cell carcinoma. Crit Rev Oncol Hematol 46 (2003) S59-S65
50. Singhal S., Mehta J., Desikan R., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341 (1999) 1565-1571
51. Eisen T., Boshoff C., Mak I., et al. Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 82 (2000) 812-817
52. Sninivas S., and Guardino A.F. Randomized phase II trial of high and low dose thalidomide in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 21 (2002) 147b (abstr)
53. Li Z., Amato R., Papandreou C., et al. Phase II study of thalidomide for patients with metastatic renal cell carcinoma (MRCC) progressing after interleukin-2 (IL-2)-based therapy. Proc Am Soc Clin Oncol 20 (2001) 180a (abstr)
54. Motzer R.J., Berg W., Ginsburg M., et al. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 20 (2002) 302-306
55. Novik Y., Dutcher J.P., Larkin M., et al. Phase II study of thalidomide (T) in advanced refractory metastatic renal cell cancer (MRCC); a single institution experience. Proc Am Soc Clin Oncol 20 (2001) 265a (abstr)